BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 18790455)

  • 1. Cellular immunotherapy for multiple myeloma.
    Rosenblatt J; Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active immunotherapy of multiple myeloma.
    Houet L; Veelken H
    Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-based immunotherapy for multiple myeloma: current approaches.
    Zhou FL; Meng S; Zhang WG; Wei YC; Cao XM; Bai GG; Wang BY
    Vaccine; 2010 Aug; 28(37):5939-46. PubMed ID: 20619381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic strategies for the treatment of plasma cell malignancies.
    Treon SP; Raje N; Anderson KC
    Semin Oncol; 2000 Oct; 27(5):598-613. PubMed ID: 11049026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in multiple myeloma--possibility or probability?
    Harrison SJ; Cook G
    Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
    Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
    Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
    Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
    Falkenburg JH; Willemze R
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic.
    Gibson J; Ho PJ; Joshua D
    Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of multiple myeloma: the start of a long and tortuous journey.
    Harrison SJ; Cook G; Nibbs RJ; Prince HM
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1769-85. PubMed ID: 17181491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of biotherapy in multiple myeloma].
    Petrucci MT; Tafuri A; Mandelli F
    Recenti Prog Med; 2000 Oct; 91(10):488-93. PubMed ID: 11072735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of anti-tumor immunity by lyophilized myeloma cells secreting GM-CSF.
    Wu S; Yuan D; Liu JN; Tan XY
    Oncol Rep; 2007 Jan; 17(1):129-33. PubMed ID: 17143489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.
    Slavin S
    Acta Haematol; 2005; 114(4):214-20. PubMed ID: 16269861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.
    Danylesko I; Beider K; Shimoni A; Nagler A
    Clin Dev Immunol; 2012; 2012():753407. PubMed ID: 22649466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.
    Danylesko I; Shimoni A; Nagler A
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S330-48. PubMed ID: 24290219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody-based immunotherapy for multiple myeloma.
    Danylesko I; Beider K; Shimoni A; Nagler A
    Immunotherapy; 2012 Sep; 4(9):919-38. PubMed ID: 23046236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunodeficiency and immunotherapy in multiple myeloma.
    Pratt G; Goodyear O; Moss P
    Br J Haematol; 2007 Sep; 138(5):563-79. PubMed ID: 17686051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.